Skip to main content

Curis Inc(CRIS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Curis Provides First Quarter 2023 Business Update

PR Newswire - Thu May 4, 2023

Company expects to discuss lifting of partial clinical hold on emavusertib with FDA in Q3

Curis strengthens executive team with appointment of industry veteran Jonathan Zung, Ph.D. as Chief Development Officer

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe